Understanding how general practitioners manage heart failure
The Role of the GP in the Management of Ambulatory Heart Failure
This study looks at why doctors might not be giving the best heart failure treatments to patients who have been hospitalized and are not getting the care they need.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Trial ID | NCT05056649 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the reasons cited by general practitioners for the under-treatment of patients with heart failure and impaired ejection fraction. It focuses on the three main treatments for this condition: ACE inhibitors, ARBs, and beta-blockers. By analyzing the treatment patterns and barriers faced by GPs, the study seeks to identify gaps in care and improve management strategies for heart failure patients. The study will include patients who have been hospitalized for cardiac decompensation and are currently receiving suboptimal treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with heart failure with impaired ejection fraction who are under 85 years old and have been hospitalized for cardiac decompensation.
Not a fit: Patients who may not benefit from this study include those who are minors, do not have a general practitioner, or object to the use of their data.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols and better management of heart failure in patients.
How similar studies have performed: While this study addresses a common issue in heart failure management, similar observational studies have shown varying degrees of success in identifying treatment gaps and improving patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a previous diagnosis of heart failure with impaired ejection fraction (LVEF \< 40%) * Under 85 years of age * Admitted to an Emergency department for cardiac decompensation * Hospitalized following this decompensation * Not deceased within one month of hospitalisation * Whose sum of the doses of ACEI or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient\* (definition in annex) * Who did not object within one month of being informed Exclusion Criteria:- Patient objecting to the use of their data * Patient who is a minor * Patient who does not have a general practitioner
Where this trial is running
Vandœuvre-lès-Nancy
- CHRU of Nancy — Vandœuvre-lès-Nancy, France (Recruiting)
Study contacts
- Study coordinator: Jean-Marc BOIVIN, MD,PhD
- Email: jm.boivin@chru-nancy.fr
- Phone: 3 83 15 73 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.